Cary Street Partners Investment Advisory LLC Grows Stake in West Pharmaceutical Services, Inc. (NYSE:WST)

Cary Street Partners Investment Advisory LLC increased its position in shares of West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) by 182.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 770 shares of the medical instruments supplier’s stock after buying an additional 497 shares during the period. Cary Street Partners Investment Advisory LLC’s holdings in West Pharmaceutical Services were worth $271,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in WST. Artisan Partners Limited Partnership lifted its position in shares of West Pharmaceutical Services by 57.2% in the 3rd quarter. Artisan Partners Limited Partnership now owns 1,591,271 shares of the medical instruments supplier’s stock worth $597,061,000 after purchasing an additional 578,796 shares during the period. Northern Trust Corp increased its holdings in shares of West Pharmaceutical Services by 4.4% in the 3rd quarter. Northern Trust Corp now owns 806,103 shares of the medical instruments supplier’s stock valued at $302,458,000 after acquiring an additional 33,867 shares during the period. Morgan Stanley increased its holdings in shares of West Pharmaceutical Services by 8.8% in the 3rd quarter. Morgan Stanley now owns 750,306 shares of the medical instruments supplier’s stock valued at $281,524,000 after acquiring an additional 60,927 shares during the period. Massachusetts Financial Services Co. MA bought a new position in shares of West Pharmaceutical Services in the 3rd quarter worth $215,011,000. Finally, Findlay Park Partners LLP lifted its stake in shares of West Pharmaceutical Services by 65.2% during the 4th quarter. Findlay Park Partners LLP now owns 457,306 shares of the medical instruments supplier’s stock worth $161,027,000 after purchasing an additional 180,415 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have commented on the stock. StockNews.com lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Friday, February 16th. UBS Group cut their price target on shares of West Pharmaceutical Services from $400.00 to $375.00 and set a “neutral” rating on the stock in a report on Friday, February 16th. Jefferies Financial Group upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and increased their price objective for the company from $323.00 to $536.00 in a report on Wednesday, February 7th. Finally, KeyCorp upped their target price on West Pharmaceutical Services from $440.00 to $470.00 and gave the company an “overweight” rating in a research report on Tuesday, February 13th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $435.20.

Read Our Latest Report on West Pharmaceutical Services

West Pharmaceutical Services Stock Performance

Shares of WST opened at $351.46 on Thursday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.95 and a current ratio of 2.61. The stock has a 50-day moving average of $378.59 and a two-hundred day moving average of $363.38. The stock has a market cap of $25.60 billion, a P/E ratio of 46.37, a P/E/G ratio of 6.31 and a beta of 1.05. West Pharmaceutical Services, Inc. has a one year low of $310.42 and a one year high of $415.73.

West Pharmaceutical Services (NYSE:WSTGet Free Report) last released its earnings results on Thursday, April 25th. The medical instruments supplier reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.29 by $0.27. West Pharmaceutical Services had a return on equity of 20.57% and a net margin of 19.42%. The firm had revenue of $695.40 million during the quarter, compared to the consensus estimate of $670.62 million. During the same quarter in the previous year, the company posted $1.98 earnings per share. The company’s revenue was down 3.0% compared to the same quarter last year. As a group, research analysts predict that West Pharmaceutical Services, Inc. will post 7.78 EPS for the current year.

West Pharmaceutical Services Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 7th. Investors of record on Wednesday, July 31st will be issued a dividend of $0.20 per share. The ex-dividend date is Wednesday, July 31st. This represents a $0.80 annualized dividend and a dividend yield of 0.23%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 10.55%.

Insider Activity at West Pharmaceutical Services

In other West Pharmaceutical Services news, CEO Eric Mark Green sold 66,000 shares of the stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the sale, the chief executive officer now directly owns 152,908 shares of the company’s stock, valued at approximately $56,063,718.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Eric Mark Green sold 66,000 shares of the company’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total value of $24,198,900.00. Following the sale, the chief executive officer now owns 152,908 shares in the company, valued at $56,063,718.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Chad Winters sold 815 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $358.82, for a total value of $292,438.30. Following the transaction, the chief accounting officer now owns 1,309 shares of the company’s stock, valued at $469,695.38. The disclosure for this sale can be found here. Insiders sold 139,978 shares of company stock worth $50,852,672 over the last three months. Company insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Profile

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Read More

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WSTFree Report).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.